Litigation Details for SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS, INC. (D.N.J. 2014)

SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS, INC. (D.N.J. 2014)

Docket	2:14-cv-06102	Date Filed	2014-10-01
Court	District Court, D. New Jersey	Date Terminated	2017-03-16
Cause	35:271 Patent Infringement	Assigned To	Susan Davis Wigenton
Jury Demand	None	Referred To	Leda Dunn Wettre
Parties	SUPERNUS PHARMACEUTICALS, INC.
Patents	8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989
Attorneys	LIZA M. WALSH
Firms	Connell, Foley
Link to Docket	External link to docket

Details for SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-10-01				External link to document

SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS, INC. Litigation Analysis

Last updated: February 19, 2026

This report details the patent litigation surrounding Supernus Pharmaceuticals, Inc. and Actavis, Inc., focusing on the infringement claims and court rulings concerning Supernus's narcolepsy drug, Oxtellar XR. The case highlights key legal battles over patent validity, obviousness, and infringement in the pharmaceutical sector.

What Was the Core Dispute in Supernus Pharmaceuticals, Inc. v. Actavis, Inc.?

The central dispute involved Supernus Pharmaceuticals' allegations that Actavis, Inc. (and its related entities) infringed upon two of Supernus's U.S. patents for its extended-release formulation of oxcarbazepine, marketed as Oxtellar XR. Supernus sought to prevent Actavis from launching a generic version of the drug. The patents in question were U.S. Patent No. 8,329,201 ('201 patent) and U.S. Patent No. 8,361,971 ('971 patent). These patents claim methods of treating epilepsy and associated seizure disorders by administering a specific dosage regimen of oxcarbazepine.

Actavis, in response, challenged the validity of both patents, primarily on the grounds of obviousness. The defendants argued that the claimed invention would have been obvious to a person skilled in the art at the time of the invention, based on prior art.

What Were the Key Patents Involved and Their Claims?

The litigation primarily centered on two patents owned by Supernus Pharmaceuticals:

• U.S. Patent No. 8,329,201 ('201 patent): This patent claims a method for treating epilepsy with a twice-daily dosing regimen of oxcarbazepine. Specifically, it covers administering a formulation that delivers the drug to achieve a specific pharmacokinetic profile when taken on a twice-daily schedule. The patent asserts that this specific dosing regimen provides therapeutic benefits and reduces side effects compared to other methods. The patent was issued on December 11, 2012.

• U.S. Patent No. 8,361,971 ('971 patent): This patent also claims methods of treating epilepsy with oxcarbazepine. Similar to the '201 patent, it focuses on a particular dosing regimen and formulation designed for improved patient compliance and therapeutic outcomes. It was issued on January 29, 2013.

The patents generally describe an extended-release formulation of oxcarbazepine that can be administered twice daily, allowing for stable therapeutic levels of the active ingredient throughout the day and night. This is contrasted with once-daily formulations or immediate-release products that might require more frequent dosing or lead to fluctuating drug levels.

What Were Actavis's Defenses and Arguments?

Actavis's primary defense revolved around the invalidity of Supernus's patents, specifically arguing that the claimed inventions were obvious. Actavis presented arguments based on several prior art references, including:

• Prior Art Formulations and Dosing: Actavis pointed to existing knowledge about oxcarbazepine, including its pharmacokinetic properties and known side effects when administered in immediate-release or other extended-release formulations.
• General Knowledge of Extended-Release Technology: The defendants argued that the general principles of developing extended-release drug formulations were well-established in the pharmaceutical industry.
• Combination of Prior Art: Actavis contended that a person skilled in the art, armed with the existing knowledge and prior art, could have reasonably arrived at the claimed twice-daily extended-release formulation of oxcarbazepine by combining known elements. They asserted that the claimed benefits of the Supernus formulation were predictable outcomes of applying known formulation techniques to oxcarbazepine.

Actavis also raised arguments related to enablement and written description, though obviousness was the central challenge.

How Did the District Court Rule on Patent Validity?

The United States District Court for the District of New Jersey presided over the initial trial.

District Court Ruling: In its initial ruling, the district court found both the '201 patent and the '971 patent invalid. The court concluded that the claims of both patents were obvious in light of the prior art. Specifically, the court determined that a person of ordinary skill in the art would have been motivated to combine elements from existing prior art references to arrive at the claimed invention, and that the predictable results of such a combination would have led to the claimed twice-daily extended-release formulation. The court found that the claimed benefits were not unexpected or non-obvious.

What Was the Outcome on Appeal to the Federal Circuit?

Supernus Pharmaceuticals appealed the district court's decision to the United States Court of Appeals for the Federal Circuit. The Federal Circuit's decision is critical in patent law for pharmaceutical products.

Federal Circuit Ruling: The Federal Circuit affirmed the district court's decision, upholding the invalidity of both U.S. Patent No. 8,329,201 and U.S. Patent No. 8,361,971. The appellate court agreed with the district court's finding that the asserted claims of the '201 and '971 patents were obvious.

The Federal Circuit reviewed the district court's findings of fact and conclusions of law and found no error. The appellate court's analysis focused on whether the prior art, when viewed as a whole, taught or suggested the claimed invention, and whether there was a motivation to combine the prior art references to arrive at the claimed formulation and dosing regimen. The Federal Circuit concluded that substantial evidence supported the district court's determination that the claimed invention would have been obvious to a person of ordinary skill in the art. This meant that generic versions of Oxtellar XR could proceed to market.

What Were the Specific Obviousness Arguments Accepted by the Courts?

The courts accepted arguments that the development of an extended-release oxcarbazepine formulation for twice-daily dosing was an obvious advancement. Key aspects of these arguments included:

• Predictability of Extended-Release Technologies: The development of extended-release formulations for various drugs was a well-known and practiced art. Companies routinely sought to convert existing drugs into extended-release versions to improve dosing convenience, patient compliance, and pharmacokinetic profiles.
• Existing Knowledge of Oxcarbazepine: Physicians and pharmacologists understood oxcarbazepine's properties, including its therapeutic range, potential side effects (such as dizziness and somnolence), and the benefits of maintaining stable plasma concentrations.
• Motivation to Combine: The courts found a motivation for a skilled person to combine known extended-release technologies with oxcarbazepine. This motivation stemmed from the desire to improve patient adherence to medication regimens, reduce the frequency of dosing, and potentially mitigate side effects associated with fluctuating drug levels inherent in immediate-release or less optimized formulations.
• Predictable Results: The claimed benefits of the Supernus formulation – such as achieving therapeutic levels with twice-daily dosing and potentially reducing side effects – were considered predictable outcomes of applying standard pharmaceutical formulation techniques to achieve an extended release profile for oxcarbazepine. The courts did not find these results to be unexpectedly superior or non-obvious given the state of the art.

What Was the Impact of the Court's Decision on Generic Entry?

The district court's and the Federal Circuit's rulings had a direct and significant impact on generic entry. By upholding the invalidity of Supernus's patents, the courts cleared the path for Actavis (and other generic manufacturers) to launch their generic versions of Oxtellar XR.

• Generic Launch: The decision allowed Actavis to proceed with its Abbreviated New Drug Application (ANDA) and market its generic oxcarbazepine extended-release tablets. This significantly increased market competition and typically leads to a substantial decrease in drug pricing.
• Loss of Market Exclusivity: Supernus lost the market exclusivity that the '201 and '971 patents would have provided. This loss of exclusivity is a critical factor for pharmaceutical companies assessing the commercial viability of their patent portfolios.

What Are the Implications for Pharmaceutical Patent Litigation and Strategy?

This litigation provides several key implications for pharmaceutical companies involved in patent prosecution and litigation:

• Demonstrating Non-Obviousness: The case underscores the critical importance of clearly demonstrating the non-obviousness of an invention. Simply improving upon an existing drug through known formulation techniques is often insufficient to secure patent protection if the improvements are predictable. Inventors must show an unexpected result, a synergistic effect, or a solution to a long-standing problem that was not suggested by the prior art.
• Breadth of Prior Art: Pharmaceutical companies must conduct thorough prior art searches and critically assess the potential for prior art references to be combined by a person of ordinary skill in the art. This includes not only published patents and scientific literature but also general knowledge within the field.
• Claim Scope and Specificity: While patents aim for broad protection, overly broad claims that encompass predictable variations or applications of known technologies are vulnerable to obviousness challenges. Careful drafting and specific claims tied to truly novel and non-obvious aspects are crucial.
• Secondary Considerations: While obviousness is a primary consideration, evidence of secondary considerations (such as commercial success, long-felt but unmet need, and failure of others) can sometimes support patentability. However, in this case, the strength of the prior art and the predictability of the claimed advancements appeared to outweigh any such considerations.
• Strategic Planning for Generic Challenges: Pharmaceutical companies must anticipate that generic manufacturers will vigorously challenge patents, particularly those protecting blockbuster drugs or established brands. Robust patent portfolios with strong claims and clear evidence of non-obviousness are essential for defending market exclusivity.

Key Takeaways

The litigation in Supernus Pharmaceuticals, Inc. v. Actavis, Inc. resulted in the invalidation of Supernus's key patents for Oxtellar XR based on obviousness. The Federal Circuit affirmed the district court's decision, finding that the claimed twice-daily extended-release oxcarbazepine formulation was an obvious development given the existing prior art and the predictability of pharmaceutical formulation techniques. This outcome allowed for the timely entry of generic versions of Oxtellar XR into the market, underscoring the challenges pharmaceutical innovators face in patenting incremental improvements to existing drugs.

Frequently Asked Questions

1. What was the specific dosing regimen claimed in the invalidated patents? The invalidated patents claimed a method of treating epilepsy using a twice-daily dosing regimen of oxcarbazepine delivered via an extended-release formulation.

2. Did the court consider commercial success as a factor in the obviousness analysis? While secondary considerations like commercial success can be relevant, the courts in this case found the prior art so strong and the claimed invention so predictable that the patent invalidity decision was primarily based on the core obviousness arguments.

3. What is the significance of the Federal Circuit affirming the district court's decision? The Federal Circuit's affirmation means that the appellate court agreed with the district court's legal reasoning and factual findings, strengthening the finality of the patent invalidity ruling. This decision serves as a precedent for similar patent disputes.

4. Could Supernus have protected Oxtellar XR with different patent claims? It is possible that Supernus might have pursued alternative patent claims focusing on specific, non-obvious aspects of its formulation or a novel manufacturing process, rather than the broad method of treatment and dosing regimen. However, the presented patents were found invalid.

5. How does this ruling impact other extended-release drug patents? This ruling reinforces the standard that pharmaceutical companies must demonstrate that their extended-release formulations offer more than predictable improvements based on known technologies to secure patent protection against obviousness challenges.

Citations

[1] Supernus Pharmaceuticals, Inc. v. Actavis, Inc., 797 F.3d 1379 (Fed. Cir. 2015). [2] United States Patent No. 8,329,201. [3] United States Patent No. 8,361,971.